


Mitigating the Impact of Missing Data in High Stakes CGT Trials

Introduction

As the number of Cell and Gene Therapy (CGT) trials grows and complexity increases, missing data becomes one of the most critical challenges to manage for trial success.



95%
of trials experience missing data¹ with CGT particularly affected due to small patient groups and long follow-ups

Up to 3x
more lab analyses in CGT trials^{2,3} make data management more complex and prone to gaps

Why Missing Data Poses Higher Risks

Missing data is common across clinical trials, but CGT trials face unique challenges that make it especially critical to address. Small patient populations, extended follow-up periods, and complex study designs all contribute to higher risks. Patient dropouts, missed visits, and other factors contribute to this, leading to:



Specialist Insights on Managing Missing Data

To mitigate missing values in small CGT populations, Emmes leverages various techniques that may not be common use in other therapy areas, such as:

Last Observation Carried Forward
A method used when repeated measures have been taken over time. The last observed value prior to the missing value is used to fill in the missing value.

Imputation
Replace an absent value with one that fits into the pattern established by the existing data points.

Censoring
A technique used to address a situation in which a value or observation is only partially known, either because the event occurs outside of the study period or because a value occurs outside the range of the measuring instrument.

Pioneering CGT Success Through Innovation and Expertise

With over 35 years of experience and more than 125 CGT trials, Emmes combines innovation, AI-driven solutions, and specialized expertise to deliver faster, high-quality outcomes. Our dedicated teams ensure success from trial design to regulatory approval, guiding sponsors every step of the way.

1 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247714/>
 2 <https://www.oncology-central.com/overcoming-data-flow-challenges-in-cell-therapy-trials-an-interview-with-olivier-saulin/>
 3 <https://www.labcorp.com/cell-and-gene-therapy-answers-bioanalytical-support-cell-and-gene-therapy>



Partner with Emmes to Accelerate Your CGT Success.
 Learn More at emmes.com/cell-and-gene-therapy